![Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - The Lancet Neurology Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/5584d24a-1666-42dc-9be9-55d76014e9f9/gr1.gif)
Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - The Lancet Neurology
![Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care ... Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care ...](https://cyberleninka.org/viewer_images/1315642/f/1.png)
Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care ...
![Design of Major Randomized Trials: Part 3 of a 4-Part Series on Statistics for Clinical Trials - ScienceDirect Design of Major Randomized Trials: Part 3 of a 4-Part Series on Statistics for Clinical Trials - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0735109715071016-gr1.jpg)
Design of Major Randomized Trials: Part 3 of a 4-Part Series on Statistics for Clinical Trials - ScienceDirect
![Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded- endpoint, randomised controlled trial - The Lancet Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded- endpoint, randomised controlled trial - The Lancet](https://www.thelancet.com/cms/asset/13767ca5-bec0-4a0b-bf76-a7de762bb086/gr1.jpg)
Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded- endpoint, randomised controlled trial - The Lancet
![Heart Rehabilitation in patients awaiting Open heart surgery targeting to prevent Complications and to improve Quality of life (Heart-ROCQ): study protocol for a prospective, randomised, open, blinded endpoint (PROBE) trial | BMJ Heart Rehabilitation in patients awaiting Open heart surgery targeting to prevent Complications and to improve Quality of life (Heart-ROCQ): study protocol for a prospective, randomised, open, blinded endpoint (PROBE) trial | BMJ](https://bmjopen.bmj.com/content/bmjopen/9/9/e031738/F1.large.jpg?width=800&height=600&carousel=1)
Heart Rehabilitation in patients awaiting Open heart surgery targeting to prevent Complications and to improve Quality of life (Heart-ROCQ): study protocol for a prospective, randomised, open, blinded endpoint (PROBE) trial | BMJ
Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded- endpoint trial
![Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial - The Lancet Neurology Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/2000992320/2003665170/gr1.gif)
Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial - The Lancet Neurology
![PPT - Blinding or Masking of Treatments and Other Aspects of the Trial PowerPoint Presentation - ID:2947805 PPT - Blinding or Masking of Treatments and Other Aspects of the Trial PowerPoint Presentation - ID:2947805](https://image1.slideserve.com/2947805/blinding-in-a-non-blind-study-l.jpg)
PPT - Blinding or Masking of Treatments and Other Aspects of the Trial PowerPoint Presentation - ID:2947805
![PDF] Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care setting | Semantic Scholar PDF] Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care setting | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/bcf01c43e4cd92f14a77bc86cd0ac0a2db6a2dc1/16-Figure1-1.png)
PDF] Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care setting | Semantic Scholar
![PDF) Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care setting | Wolfram Ziegler - Academia.edu PDF) Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care setting | Wolfram Ziegler - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/72859256/mini_magick20211016-2254-1vv75ax.png?1634407857)
PDF) Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care setting | Wolfram Ziegler - Academia.edu
![Frontiers | Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol Frontiers | Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol](https://www.frontiersin.org/files/Articles/1248468/fcvm-10-1248468-HTML-r1/image_m/fcvm-10-1248468-g001.jpg)
Frontiers | Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol
![A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study | Semantic Scholar A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a80a8b9dcae6dce8ccd42713ad1e8fcf798c1403/4-Table2-1.png)
A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study | Semantic Scholar
![Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial - The Lancet Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial - The Lancet](https://www.thelancet.com/cms/asset/8e2715b8-4a0b-4717-ac70-7d7ee212f889/gr1.jpg)
Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial - The Lancet
![PPT - Blinding or Masking of Treatments and Other Aspects of the Trial PowerPoint Presentation - ID:2947805 PPT - Blinding or Masking of Treatments and Other Aspects of the Trial PowerPoint Presentation - ID:2947805](https://image1.slideserve.com/2947805/probe-design-l.jpg)
PPT - Blinding or Masking of Treatments and Other Aspects of the Trial PowerPoint Presentation - ID:2947805
![Study overview. *PROBE: prospective randomized open blinded endpoint... | Download Scientific Diagram Study overview. *PROBE: prospective randomized open blinded endpoint... | Download Scientific Diagram](https://www.researchgate.net/publication/374778100/figure/fig1/AS:11431281199374182@1697576289728/Study-overview-PROBE-prospective-randomized-open-blinded-endpoint-design-1-primary_Q320.jpg)